Clinical trial Recruiting at 1 site Interventional Ages 18 to 45

Effects of weight loss and weight regain on androgen levels and insulin resistance in PCOS.

Official title: The Effect and Mechanism Of Weight Cycling on Hyperandrogenemia And Insulin Resistance in Polycystic Ovary Syndrome

Run by Peking Union Medical College Hospital · NCT06545721 · Data updated 2026-11-12

This program sees if a high-protein diet with exercise and behavioral support, and different amounts of weight loss or regain, improve androgen levels and insulin resistance in women with PCOS.

More Polycystic Ovary Syndrome trials

Quick facts

Study typeInterventional
Ages18 Years to 45 Years
SexAll
Enrollment425 (estimated)
SponsorPeking Union Medical College Hospital
Academic / other
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedAugust 13, 2024
Main results expectedMarch 1, 2026
Study endsApril 1, 2026
Registry record updatedDecember 3, 2025
Trial IDNCT06545721 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women aged 18–45 with PCOS by Rotterdam criteria who are willing to follow dietary, exercise, and behavioral programs and who fall into the study BMI ranges (normal 18.5–<24 kg/m2 or BMI ≥24 kg/m2) are ideal candidates.

Probably not a fit

Women who are pregnant, breastfeeding, planning pregnancy within six months, currently using prescription weight‑loss medications, with prior bariatric surgery, or with severe cardiovascular, cerebrovascular, or liver disease are unlikely to be eligible or to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, prospective cohort enrolling about 425 women with PCOS split into a normal-weight group and an overweight/obese group. Overweight/obese participants receive an intensive high-protein diet plus exercise and behavioral interventions for weight loss, while normal-weight participants receive energy-control and behavior support to prevent weight gain. Participants are followed at 3 and 6 months and categorized by percent weight change (<2%, 2–5%, 5–10%, ≥10%) to compare changes in insulin resistance, androgen levels, and inflammatory markers. The study also includes genetic/transcriptome analyses to explore molecular mechanisms linking weight change and weight cycling to PCOS manifestations.

Why it matters

Potential benefit: If successful, the results could clarify how much weight loss is needed to improve hormones and insulin resistance in PCOS and help set personalized weight‑loss targets.

How similar studies have gone: Previous research shows that modest weight loss often improves metabolic and reproductive outcomes in PCOS, but the specific effects of different weight‑loss thresholds and of weight cycling, especially at the transcriptome level, are less well characterized.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Women aged 18-45 years in the reproductive period;
2. Women who have previously met the Rotterdam diagnostic criteria (at least 2 of the following 3 criteria have been confirmed, and have been diagnosed with PCOS): 1) Oligomenorrhea and/or anovulation; 2) clinical and/or biochemical evidence of hyperandrogenism; 3) ultrasound showing the presence of unilateral or bilateral polycystic ovaries;
3. Inclusion of 50 women in the normal weight group: 18.5 kg/m² ≤ BMI \< 24 kg/m²; Inclusion of 400 women in the overweight/obese group: BMI ≥ 24 kg/m²;
4. Voluntarily participate in the intervention and sign an informed consent form.

Exclusion Criteria:

1. Currently pregnant or lactating, or have had a recent (within 6 months) plan for pregnancy;
2. Currently using known prescription weight loss medications (such as GLP-1RA, orlistat, topiramate, etc.);
3. History of weight loss surgery;
4. History of severe cardiovascular or cerebrovascular diseases; severe liver or kidney dysfunction (ALT \> 3 times the upper limit of normal, or creatinine \> 1.5 times the upper limit of normal); chronic or active gastrointestinal inflammatory diseases; severe systemic diseases; active malignant tumors;
5. Secondary obesity: including hypothalamic or pituitary obesity, obesity secondary to glucocorticoid use, hypogonadism-induced obesity, etc.;
6. Known history of serious endocrine system diseases;
7. Poor compliance with planned dietary interventions (psychiatric disorders such as binge eating disorder, anorexia nervosa, severe anxiety/depression);
8. Unable to follow up on time or deemed non-cooperative by the investigator.

Where it's running

  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

  • Principal investigator: Wei Chen, PhD — Peking Union Medical College Hospital
  • Study coordinator: Wei Chen, PhD
  • Email: txchenwei@sina.com
  • Phone: 13911006820

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.